Bio Search to Acquire Israeli Brain-AI Firm InnerEye in Share Swap

By Daniel Okafor

Japan's Bio Search announced on November 9, 2026 that it signed a share-exchange agreement to acquire 100% of InnerEye, an Israeli company that analyzes brain signals in real time with AI. The deal would turn InnerEye into a wholly owned subsidiary and fold its expert-decision technology into Bio Search's healthcare AI business.

The transaction has not closed. Completion depends on customary conditions, including approvals from Israeli authorities. Closing is scheduled between December 2026 and early January 2027.

What does InnerEye's technology actually do?

InnerEye's product documentation describes Minded A.I., a workflow for transferring aspects of expert judgment into AI models. An expert wears a device that acts as the interface. The system converts elements of that person's decisions into digital insights. Those insights teach models to reproduce expert decision patterns and support assessments of user performance and trust in the expert's decisions.

A feedback loop keeps running. It is intended to improve both the models and the experts using them. Two products build on this mentoring process:

• Sense.I applies it to AI training, personalization and optimization.
• SensePlus targets the cognitive and emotional factors behind actions, detecting fatigue, concentration and attention levels during tasks to help reduce human error.

Bio Search says InnerEye's proprietary algorithms interpret electroencephalogram (EEG) readings in real time. The goal is to distinguish cognitive states involved in perception and decision-making.

Who built the company?

InnerEye was established in 2014. Its founders are Amir Geva, a professor of electrical and computer engineering at Ben-Gurion University of the Negev, and Leon Deouell, a physician and professor of brain sciences at the Hebrew University of Jerusalem. Their combined research underpins technology designed to learn decision processes rooted in personal experience and tacit knowledge before the trained models are deployed.

How does the deal fit Bio Search's business?

Bio Search already uses EEG, electrocardiogram (ECG), heart-rate and electromyography (EMG) signals in its healthcare AI work. Its operations span biological sensing, medical-device engineering and business development in Japan and other Asian markets. The acquisition adds real-time brain-signal algorithms to that stack.

The integration plan centers on a shared platform. It would pool both companies' EEG and other biological data to train AI models, connecting Bio Search's signal capture and device design with InnerEye's models of expert judgment. Bio Search projects improvements in precision, robustness and analytical scope. It did not quantify the expected gains.

The target uses the companies have identified include:

• Visualizing cognitive function and supporting early diagnosis
• Industrial automation
• Affective computing
• Security
• Decision support for experts

InnerEye CEO Uri Antman called the combination "the ideal partnership to elevate the Brain-AI technology we have cultivated over many years into a global commercial scale."

Beyond the technical work, the companies plan a unified executive structure across Japan and Israel, plus stronger governance and internal controls. Bio Search has also set a target of a Nasdaq listing in 2028 as part of its expansion roadmap.

What happens next?

Regulatory approval and closing come first, between December 2026 and early January 2027 if the timetable holds. The harder question follows: whether pooling brain and other biological data can produce models reliable enough for the broad healthcare and industrial uses Bio Search has identified. That test will gauge how credible the 2028 Nasdaq target really is.